The Outcome of Discontinuing Tyrosine Kinase Inhibitors in Advanced Sarcoma Following a Favorable Tumor Response to Antiangiogenics Therapy

Zhusheng Zhang, Qiyuan Bao, Yucheng Fu, Junxiang Wen, Meng Li, Zhuochao Liu, Guoyu He, Beichen Wang, Yuhui Shen, Weibin ZhangJournal of Clinical Medicine 2022 · DOI

TL;DR

This study explores the feasibility of discontinuing antiangiogenic tyrosine kinase inhibitors (AA-TKIs) in advanced sarcoma patients who have achieved a significant tumor response. The findings suggest that a carefully selected group of patients, particularly those who achieved surgical complete remission and underwent a gradual drug tapering-off strategy, may safely discontinue AA-TKIs with acceptable outcomes.

What Problem Does This Paper Address?

Advanced sarcomas are notoriously difficult to treat, often with limited therapeutic options beyond initial lines of chemotherapy. Antiangiogenic tyrosine kinase inhibitors (AA-TKIs) have emerged as a promising treatment modality, showing significant tumor responses in some patients. However, for patients who achieve a near-complete or complete remission, the question of whether to continue these drugs indefinitely, or if a "drug holiday" is possible, remains largely unexplored. This poses challenges related to long-term toxicity, patient quality of life, and the potential for developing resistance. This paper addresses the critical question of whether discontinuing AA-TKIs after a favorable response is safe and what factors might predict successful outcomes.

Methods

The researchers conducted a retrospective analysis of 22 advanced sarcoma patients who discontinued AA-TKIs after demonstrating a favorable response (near-complete or complete remission, or long-term responders). Patients were included if they had characteristics suggesting a poor prognosis prior to AA-TKI initiation, such as multiple lung metastases or a short disease-free interval.

Key methodological aspects include:

  • Patient Selection: Strict criteria were applied to identify patients with a significant response to AA-TKIs.
  • Discontinuation Strategies: Patients either abruptly stopped AA-TKIs or used a "taper-off" strategy, involving gradual dose reduction.
  • Outcome Assessment: The study tracked progression-free survival post-discontinuation (pd-PFS), overall survival post-discontinuation (pd-OS), and relapse-free survival post-discontinuation (pd-RFS).
  • Biomarker Analysis: The researchers investigated potential prognostic factors, including tumor necrosis rates and neutrophil-to-lymphocyte ratios (NLR), before drug discontinuation.
  • Statistical Analysis: Kaplan-Meier analysis was used to assess survival outcomes and identify significant prognostic factors.

Datasets

Not discussed in the paper. The study utilized retrospective clinical data from 22 patients treated at a specific institution.

Key Insights and Ideas

  • Drug Holidays are Possible, But Highly Selective: The study demonstrates that discontinuing AA-TKIs is not universally applicable but can be a safe and feasible option for a carefully selected subset of advanced sarcoma patients.
  • Surgical Complete Remission is a Strong Predictor: Achieving a surgical complete remission (CR) before discontinuing AA-TKIs appears to be a crucial factor for better outcomes.
  • Tapering Off is Superior to Abrupt Stopping: A gradual "taper-off" strategy for drug discontinuation was significantly associated with improved relapse-free and overall survival compared to abrupt cessation. This suggests a gentler approach may mitigate the risk of rapid tumor rebound.
  • Tumor Necrosis and NLR as Potential Biomarkers: Higher tumor necrosis rates and lower neutrophil-to-lymphocyte ratios (NLR) before discontinuation were associated with better relapse-free survival, suggesting these could be valuable indicators for patient selection.
  • Second CRs are Achievable: Even after disease progression post-discontinuation, a significant portion of patients were still sensitive to AA-TKIs or amenable to surgical intervention, leading to second complete remissions.

Key Results

  • Disease Progression is Common: A substantial majority of patients (77.3%) experienced disease progression after discontinuing AA-TKIs, with a median time to progression of 4.2 months.
  • Favorable Relapse-Free Survival: Despite progression, 54.5% of patients remained relapse-free at the last follow-up, with a median follow-up of 25.1 months.
  • Improved Survival with Taper-Off: The taper-off strategy was associated with significantly greater pd-RFS and pd-OS compared to abrupt discontinuation.
  • Surgical CR Impact: Patients who achieved surgical CR before discontinuation had a greater pd-RFS and pd-OS.
  • Biomarker Associations: Higher tumor necrosis rates (p=0.040) and lower NLR (p=0.060) were linked to better pd-RFS.

Limitations and Future Work

The authors acknowledge several limitations:

  • Small Sample Size: The study included only 22 patients, which is a small number due to the rarity of achieving near-complete remission in advanced sarcoma with AA-TKIs.
  • Retrospective Design: The retrospective nature of the study introduces potential biases in patient selection and data collection.
  • Lack of Control Group: The absence of a control group receiving continuous AA-TKI therapy makes direct comparison of oncological outcomes challenging.

Future work should focus on:

  • Larger Prospective Studies: Conducting larger, prospective studies with control groups is essential to validate these findings and establish optimal treatment protocols.
  • Optimal Duration of Maintenance Therapy: Further investigation is needed to determine the ideal duration of AA-TKI maintenance therapy before considering discontinuation.
  • Biomarker Validation: More research is required to validate the prognostic value of tumor necrosis rates and NLR in predicting outcomes after AA-TKI withdrawal.
  • Understanding Mechanisms: Further exploration into the biological mechanisms underlying the benefits of tapering off and the role of tumor quiescence could provide deeper insights.

Summary updated

Abstract

(1) Background: The use of antiangiogenic TKIs (AA-TKIs) has recently emerged as a major paradigm shift in the treatment of advanced sarcoma. However, the feasibility of drug holidays for patients demonstrating a very favorable response remains unknown. (2) Methods: We aim to explore the outcomes of patients with advanced sarcoma who discontinued AA-TKIs after a (near-) complete remission or were long-term responders. Patients with advanced disease were included if they had bilateral or multiple lung metastases, extrapulmonary recurrence, a short disease-free interval, etc., at the initiation of AA-TKIs. (3) Results: A total of 22 patients with AA-TKI discontinuation were analyzed, with a median follow-up of 22.3 months post-discontinuation. Prior to discontinuation, there were four drug-induced complete remissions (CRs), twelve surgical CRs, and six long-term responders. Disease progression was observed in 17/22 (77.3%) patients, with a median of 4.2 months. However, since the majority were still sensitive to the original AA-TKIs and amenable to a second surgical remission, 7 out of these 17 patients achieved a second CR after disease progression and were thus considered as relapse-free post-discontinuation (pd-RFS). Therefore, the pd-RFS and post-discontinuation overall survival (pd-OS) in the last follow-up were 12/22 (54.5%) and 16/22 (72.7%), respectively. Remarkably, surgical CR and drug tapering off (versus abrupt stopping) were associated with a greater pd-RFS and pd-OS (p < 0.05). Furthermore, higher necrosis rates (p = 0.040) and lower neutrophil-to-lymphocyte ratios (NLR) (p = 0.060) before discontinuation tend to have a better pd-RFS. (4) Conclusions: Our results suggest that AA-TKI discontinuation with a taper-off strategy might be safe and feasible in highly selected patients with advanced sarcoma. Surgical CR, NLR, and tumor necrosis rates before discontinuation were potential biomarkers for AA-TKI withdrawal.
BibTeX
@article{zhang2022outcome,
  author = {Zhusheng Zhang and Qiyuan Bao and Yucheng Fu and Junxiang Wen and Meng Li and Zhuochao Liu and Guoyu He and Beichen Wang and Yuhui Shen and Weibin Zhang},
  title = {{The Outcome of Discontinuing Tyrosine Kinase Inhibitors in Advanced Sarcoma Following a Favorable Tumor Response to Antiangiogenics Therapy}},
  journal = {Journal of Clinical Medicine},
  year = {2022},
  doi = {10.3390/jcm12010325},
}
Figure